Opportunity Information: Apply for RFA AG 20 002
The National Institutes of Health (NIH) is soliciting applications for a Research and Development Center grant mechanism (P30) under the funding opportunity titled "Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (P30 Clinical Trial Optional)" (Funding Opportunity Number: RFA-AG-20-002; CFDA: 93.866). The purpose of this opportunity is to build or strengthen centers that concentrate on demography, economics, and health services research connected to Alzheimer's disease and Alzheimer's related dementias (AD/ADRD). In practical terms, the FOA is aimed at supporting institutional hubs that can organize data resources, shared infrastructure, and coordinated research programs to generate evidence that improves understanding of dementia at the population level, including how care is delivered, paid for, and experienced.
The scientific emphasis is squarely on population and systems questions rather than basic biology. NIH highlights a set of priority topics that are especially encouraged. These include national and international trends in cognitive aging and AD/ADRD, as well as the demography of dementia care and caregiving, which covers who provides care, how caregiving is structured, and how these patterns are changing over time. The FOA also prioritizes work on the economic burden of AD/ADRD, meaning analyses of costs to patients and families, health systems, insurers, and society, including direct medical spending and indirect costs such as lost productivity or uncompensated caregiving time.
A major portion of the encouraged scope centers on how health care and long-term services and supports shape outcomes. This includes studying how different health care systems and long-term care arrangements affect people living with dementia and their care partners, and how health care financing policies (for example, coverage rules, reimbursement design, and payment reforms) influence access, quality, utilization, and patient and caregiver outcomes. The FOA also explicitly calls for research on how regulatory and economic incentives affect access and quality across both health care and long-term care settings, recognizing that provider behavior and system performance are often driven by the incentives embedded in policy and payment structures.
Equity and effectiveness at scale are also central themes. NIH encourages research on disparities in access to and quality of dementia care, which can include differences by race, ethnicity, socioeconomic status, geography, disability status, or other factors that influence whether people receive timely diagnosis, appropriate treatment, and supportive services. Another encouraged topic is the effect of population-level health delivery and care interventions, meaning evaluations of large-scale programs or systemwide changes intended to improve outcomes for people with dementia and those who support them. Finally, the FOA highlights projections of dementia incidence, prevalence, and overall caseload in the United States and internationally, reflecting the need for forward-looking estimates that can guide planning for workforce, financing, caregiver support, and long-term care capacity.
From an eligibility standpoint, the announcement is broad and includes many types of U.S.-based organizations: state, county, and municipal governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly calls out additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
At the same time, there are important limits on foreign participation. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply as the applicant organization. However, foreign components are allowed under NIH policy as defined in the NIH Grants Policy Statement, which generally means a U.S. applicant may include certain foreign collaborations or activities if they are well-justified and meet NIH requirements, even though a foreign institution cannot be the primary applicant.
Administratively, this is a discretionary grant opportunity with NIH as the funding agency. The original closing date listed is 2019-06-03, and the opportunity record shows a creation date of 2018-10-30. The notice indicates that clinical trials are optional, meaning applicants can propose studies that include clinical trial elements if appropriate, but a clinical trial is not required for responsiveness. The award ceiling and expected number of awards are not specified in the provided source details, so applicants would typically need to consult the full FOA text and NIH budget guidance for any funding caps, project period expectations, and required center components.Apply for RFA AG 20 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (P30 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2018-10-30.
- Applicants must submit their applications by 2019-06-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This opportunity is a National Institutes of Health (NIH) solicitation for a Research and Development Center grant mechanism (P30) titled "Centers on the Demography and Economics of Alzheimer's Disease and Alzheimer's Related Dementias (P30 Clinical Trial Optional)." The Funding Opportunity Number is RFA-AG-20-002 and the CFDA listing provided is 93.866.
What is the main purpose of the program?
The purpose is to build or strengthen institutional centers that focus on the demography, economics, and health services research related to Alzheimer's disease and Alzheimer's related dementias (AD/ADRD). In practical terms, the program is meant to support "hub" centers that can organize data resources, shared infrastructure, and coordinated research programs to generate evidence that improves population-level understanding of dementia, including how care is delivered, paid for, and experienced.
What types of research does NIH want these centers to focus on?
The emphasis is on population and systems questions rather than basic biology. The centers are expected to concentrate on research areas connected to demography, economics, and health services related to AD/ADRD.
Is basic biology or lab-based Alzheimer's research a focus of this opportunity?
No. The stated scientific emphasis is on population and systems questions (demography, economics, health services research), not basic biology.
What priority research topics are especially encouraged?
NIH highlights several encouraged topics, including:
- National and international trends in cognitive aging and AD/ADRD.
- The demography of dementia care and caregiving (who provides care, how caregiving is structured, and how patterns are changing over time).
- The economic burden of AD/ADRD, including direct medical spending and indirect costs (such as lost productivity and uncompensated caregiving time).
- How health care systems and long-term services and supports affect outcomes for people living with dementia and their care partners.
- How health care financing policies (coverage rules, reimbursement design, payment reforms) influence access, quality, utilization, and patient/caregiver outcomes.
- How regulatory and economic incentives affect access and quality across health care and long-term care settings.
- Disparities in access to and quality of dementia care (by race, ethnicity, socioeconomic status, geography, disability status, and other relevant factors).
- Effects of population-level health delivery and care interventions (large-scale programs or systemwide changes).
- Projections of dementia incidence, prevalence, and overall caseload in the U.S. and internationally.
What does "demography of dementia care and caregiving" mean in this FOA?
In this context, it refers to studying who provides dementia care, how caregiving arrangements are structured, and how those caregiving patterns and caregiving populations are changing over time.
What does NIH mean by the "economic burden" of AD/ADRD?
The economic burden includes costs to patients and families, health systems, insurers, and society. It can include direct medical spending as well as indirect costs such as lost productivity or the value of uncompensated caregiving time.
What kinds of health system or long-term care questions fit this opportunity?
The encouraged scope includes studying how different health care systems and long-term services and supports affect outcomes for people with dementia and their care partners, and how financing policies and incentives shape access, quality, utilization, and outcomes across health care and long-term care settings.
Does the FOA prioritize work on policy and incentives?
Yes. The FOA explicitly calls for research on how regulatory and economic incentives influence access and quality in both health care and long-term care settings, reflecting the idea that provider behavior and system performance are shaped by policy and payment structures.
Are health equity and disparities part of the encouraged scope?
Yes. NIH encourages research on disparities in access to and quality of dementia care. Examples mentioned include differences by race, ethnicity, socioeconomic status, geography, disability status, and other factors that affect whether people receive timely diagnosis, appropriate treatment, and supportive services.
Are evaluations of large-scale interventions or programs encouraged?
Yes. The FOA encourages research on the effects of population-level health delivery and care interventions, including evaluations of large-scale programs or systemwide changes intended to improve outcomes for people with dementia and their care partners.
Does this FOA encourage forecasting or projection work?
Yes. Projections of dementia incidence, prevalence, and overall caseload in the United States and internationally are specifically highlighted as an encouraged topic to support planning for workforce, financing, caregiver support, and long-term care capacity.
What grant mechanism is being used?
The mechanism is a Research and Development Center grant (P30), intended to support centers (institutional hubs) with shared infrastructure and coordinated research programs.
Are clinical trials required?
No. The FOA indicates "Clinical Trial Optional," meaning clinical trial elements may be included if appropriate, but clinical trials are not required for an application to be responsive.
Who is the funding agency?
The funding agency is the National Institutes of Health (NIH).
What is the Funding Opportunity Number and CFDA number?
The Funding Opportunity Number is RFA-AG-20-002 and the CFDA number provided is 93.866.
What is the application due date listed in the provided information?
The original closing date listed is 2019-06-03.
What is the opportunity record creation date listed?
The opportunity record shows a creation date of 2018-10-30.
What types of U.S. organizations are eligible to apply?
The eligibility described is broad and includes many U.S.-based organizations, including:
- State, county, and municipal governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities/Indian housing authorities
- Nonprofits with 501(c)(3) status and nonprofits without 501(c)(3) status
- For-profit organizations (other than small businesses)
- Small businesses
- Faith-based or community-based organizations
- Eligible federal agencies
- Regional organizations
- U.S. territories or possessions
Are minority-serving institutions explicitly included as eligible applicants?
Yes. The FOA explicitly calls out additional eligible applicant categories including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs).
Can a non-U.S. (foreign) organization apply as the primary applicant?
No. Non-domestic (non-U.S.) entities are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply as the applicant organization.
Are foreign collaborations allowed at all?
Yes, foreign components are allowed under NIH policy as defined in the NIH Grants Policy Statement. This generally means a U.S. applicant may include certain foreign collaborations or activities if they are well-justified and meet NIH requirements, even though a foreign institution cannot serve as the primary applicant.
Is the award ceiling or the expected number of awards provided in the information shown?
No. The award ceiling and expected number of awards are not specified in the provided details.
Where should applicants look for funding caps, project period expectations, and required center components?
Based on the information provided, applicants would typically need to consult the full FOA text and NIH budget guidance for details such as any funding caps, project period expectations, and required center components.
Is this a discretionary grant opportunity?
Yes. The opportunity is described as a discretionary grant opportunity with NIH as the funding agency.
What kind of impact is NIH aiming for with these centers?
The FOA is aimed at producing evidence that improves understanding of dementia at the population level, including how dementia care is delivered, financed, and experienced, and how systems and policies influence outcomes for people living with dementia and their care partners.
Browse more opportunities from the same category: Health
Next opportunity: Enhancing Agricultural Opportunities for Military Veterans
Previous opportunity: Novel Approaches for Relating Genetic Variation to Function and Disease (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AG 20 002
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AG 20 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Novel Approaches for Relating Genetic Variation to Function and Disease (R43/R44 Clinical Trial Not Allowed) Apply for PA 19 043 Funding Number: PA 19 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Research in Augmentative and Alternative Communication (AAC) (R21 Clinical Trial Optional) Apply for PA 19 046 Funding Number: PA 19 046 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Advancing Research in Augmentative and Alternative Communication (AAC) (R01 Clinical Trial Optional) Apply for PA 19 047 Funding Number: PA 19 047 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed) Apply for PAR 19 048 Funding Number: PAR 19 048 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Research Directions that Advance the NHLBI Strategic Vision Normal Biology (R21 - Clinical Trial Not Allowed) Apply for PA 19 049 Funding Number: PA 19 049 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Sustainable Access for Expanded Voluntary Medical Male circumcision (VMMC) Services (SAFE) Apply for SOURCES SOUGHT NOTICE 2018 Funding Number: SOURCES SOUGHT NOTICE 2018 Agency: Tanzania USAID-Dar es Salaam Category: Health Funding Amount: Case Dependent |
| Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) Apply for RFA AG 20 004 Funding Number: RFA AG 20 004 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Investigator Initiated Research in Computational Genomics and Data Science (R43/R44 Clinical Trial Not Allowed) Apply for PAR 19 061 Funding Number: PAR 19 061 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Processing and Presentation of Non-Conventional MHC Ligands (R01 Clinical Trial Not Allowed) Apply for PA 19 067 Funding Number: PA 19 067 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single-Cell Multi-Omics of HIV Persistence (R01 Clinical Trial Not Allowed) Apply for RFA AI 18 053 Funding Number: RFA AI 18 053 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
| Processing and Presentation of Non-Conventional MHC Ligands (R21 Clinical Trial Not Allowed) Apply for PA 19 066 Funding Number: PA 19 066 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed) Apply for PA 19 068 Funding Number: PA 19 068 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed) Apply for RFA DE 19 008 Funding Number: RFA DE 19 008 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed) Apply for RFA DE 19 009 Funding Number: RFA DE 19 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Medications Development for the Treatment of Alcohol Use Disorder (U01 Clinical Trial Optional) Apply for RFA AA 19 005 Funding Number: RFA AA 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) Apply for PAR 19 070 Funding Number: PAR 19 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Not Allowed) Apply for PAR 19 071 Funding Number: PAR 19 071 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Long-acting Drug Delivery Systems for ART Optimization in HIV-1 Infected Children (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 18 057 Funding Number: RFA AI 18 057 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R21 Clinical Trial Optional) Apply for RFA MH 19 411 Funding Number: RFA MH 19 411 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting Reductions in Intersectional StigMa (PRISM) to Improve the HIV Prevention Continuum (R34 Clinical Trial Required) Apply for RFA MH 19 410 Funding Number: RFA MH 19 410 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AG 20 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.